By: M. Maerevoet MD
This report provides a summary of the most interesting presentations in the field of lymphoma at EHA 2024, including the use of glofitamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), real-world data on the use of CAR-T cells in R/R DLBCL and several bispecific antibodies that could offer an important off-the-shelf treatment option for patients with heavily pre-treated relapsed/refractory follicular lymphoma.
(BELG J HEMATOL 2024;15(5):193–6)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
